Description: A leading cGMP manufacturer of viral-based products with a strong commitment to restoring hope, purpose and a true sense of belonging for those living with chronic health conditions.
Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an unparalleled reputation in the gene therapy market.
Etelä-Savo Centre for Economic Development, Transport and the Environment has granted FinVector Oy a total of EUR 6,555,000 for the construction of new pharmaceutical manufacturing facility.
We are a cGMP manufacturer of viral-based gene therapy products that improve the lives of people battling chronic health conditions such as bladder cancer.